Business Wire

Airship Unveils Airship Journeys, Offering Brands Revolutionary Simplicity to Create, Manage and Optimize Cross-Channel Customer Experiences for the Mobile Era

18.11.2019 17:00:00 EET | Business Wire | Press release

Share

Customer engagement company Airship today introduced Airship Journeys, a new visual interface that makes customer engagement simpler and dramatically more effective for the marketer. Airship Journeys combines the power of visual sequencing and cross-channel branching with glanceable views of goal-based performance to make it easy for marketers to quickly create, manage and adapt customer engagement paths with a few clicks. Now marketers can rapidly leverage their data and models alongside Airship’s real-time mobile data, predictive AI and machine learning to create multichannel sequences that drive improved campaign outcomes and better customer experiences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191118005298/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Airship Journeys makes it easy for marketers to rapidly create and optimize multichannel message sequences to reach customers with the right information at the right moment across apps, websites, email, SMS, mobile wallets and more (Graphic: Business Wire)

Airship Journeys addresses frustrations with today’s “drag-and-drop” journey builder tools, which generate convoluted diagrams that are difficult to create and nearly impossible to understand, analyze and modify. A November 2019 Airship survey of marketers found that more than 40% deemed their efforts to manage multichannel digital communications as unsuccessful and more than half said they either have difficulty or can’t identify their best-performing journeys. Over-messaging is a concern to more than 70%, while 55% are also concerned about under-messaging.

“Legacy visual builders were created for an email- and desktop-centric world with far fewer channels and little concern for where a customer was or what they were doing,” said Brett Caine, CEO and president, Airship. “They’ve become complex and bloated in failed attempts to adapt to the new era where the customer experience is all about mobile and in-the-moment responsiveness with many more channels and a much greater expectation that interactions are personalized and contextually relevant. Airship Journeys embeds a decade of mobile expertise and proven AI into a completely new approach to ensure that marketers are successful and their customers have an amazing experience.”

By combining the management of multiple channels into a single console, Airship Journeys makes it easy for marketers to send the right messages to the right customers across apps, websites, email, SMS, mobile wallets and more. Messages can be directed according to priority channel, customer’s preferred channel or fallback channel. Marketer productivity is also enhanced with a unified message composer that allows messages to be composed once and then sent across multiple channels.

“I really like the ease of use, and linking the send time between messages which helped increase productivity for our team. Airship Journeys makes it easy to see what the user experience will look like and share that view internally,” said Conner Fryoux, Digital Product Manager, TGI Fridays. “I'm eager to test out new use cases, and our leadership team is pleased to see more customers come through our doors.”

Airship’s open platform approach also eases the consolidation and application of data and events across channels and existing systems - enabling more precise segmentation and personalized execution. To further enhance contextual responsiveness, Airship Journeys incorporates cross-channel branching that automatically adjusts in real time to respond to a customer’s behavior. Airship Journeys monitors and controls message frequency and uses Predictive AI to segment audiences and automatically re-engage lapsed customers.

“Airship Journeys allows us to make quick decisions and adapt critical journeys on the fly, from driving feature adoption and app store ratings, to increasing transaction frequency at key moments in the lifecycle, all while taking full advantage of our own predictive models and historical data,” said Sam Kirwan, app marketing specialist, Ding.com. “The massive benefit is that Journeys has freed up our time, allowing us to examine cohorts at different life stages and apply more testing as we revamp our lifecycle marketing holistically — no small feat considering our customers span more than 140 countries.”

With early use and guidance by The Allstate Corporation, Ding.com, GameStop, JCPenney, Kohl’s, NBA International and TGI Fridays, Airship Journeys has been designed to meet the complex demands of global brands and is now included in its Customer Engagement Platform.

Recently, among 18 vendors, Airship received the highest Product Scores across all three Use Cases in Gartner’s 2019 Critical Capabilities for Mobile Marketing Platforms,1 including the Acquisition, Engagement and Retention Use Cases. In Gartner’s 2019 Magic Quadrant for Mobile Marketing Platforms 2 Airship was positioned highest in its ability to execute and also furthest for its completeness of vision in the Leaders quadrant overall. Complimentary copies of the reports are available here:

1 Gartner “Critical Capabilities for Mobile Marketing Platforms” by Charles S. Golvin, Mike McGuire, October 21, 2019
2 Gartner “Magic Quadrant for Mobile Marketing Platforms” by Mike McGuire, Charles Golvin, July 15, 2019

Gartner Disclosure

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Airship

Marketing and digital experience teams at thousands of the world’s most admired companies rely on Airship’s Customer Engagement Platform to create deeper connections with customers by delivering incredibly relevant, coordinated messages across channels.

Founded in 2009 as a pioneer in push notifications, Airship now gives brands the user-level data, engagement channels, AI orchestration and services they need to deliver push notifications, emails, SMS, in-app messages, mobile wallet cards and more to exactly the right person in exactly the right moment — building trust, boosting engagement, driving action and growing value.

Learn more about our Customer Engagement Platform, read our blog or follow us on Twitter, LinkedIn, Facebook and Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

North America:
Danielle Stickler
Bateman Group
+1 415-749-9124
airship@bateman-group.com

Corey Gault
Airship
+1 503-206-9164
corey@airship.com

EMEA:
Nina Meyer
Airship
+33 1 44 56 87 10
nina.meyer@airship.com

UK:
Lucinda Layton
Hotwire UK
+44 20 7608 2500
Airship@hotwireglobal.com

France:
Marion Fajgenbaum / Marine Cressot
Hotwire France
+33 14 312 55 68 / 69
AirshipFR@hotwireglobal.com

Germany:
Julia da Silva Bastos
Hotwire Germany
+49 89 2620 81 89
airshipde@hotwireglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye